Hermetica Superfood Encyclopedia
The Short Answer
4-Hydroxyisoleucine is a rare branched-chain amino acid isolated from fenugreek seeds (Trigonella foenum-graecum) that directly stimulates pancreatic beta cells to secrete insulin in a glucose-dependent manner. Its primary mechanism involves potentiating insulin release through modulation of the sulfonylurea receptor and augmenting peripheral glucose uptake via GLUT4 transporter translocation in skeletal muscle.
CategoryBranded Ingredients
GroupOther
Evidence LevelPreliminary
Primary Keywordfenugreek 4-hydroxyisoleucine benefits
Synergy Pairings3
Fenugreek 4-Hydroxyisoleucine (Trigonella foenum-graecum) — botanical close-up
Health Benefits
Origin & History
Natural habitat
4-Hydroxyisoleucine (4-HIL) is a non-protein branched-chain amino acid derivative isolated from fenugreek seeds (Trigonella foenum-graecum L.), comprising up to 80% of free amino acids in the seeds at concentrations of 0.015%-0.4%. It is extracted and purified from fenugreek seeds to yield a white powder or flakes with ≥98% purity via TLC.
“Fenugreek seeds, the source of 4-hydroxyisoleucine, have been used in traditional medicine for antidiabetic properties, though 4-HIL itself is not explicitly historical. The plant's traditional reputation for blood sugar management is partly attributed to this compound's insulinotropic effects.”Traditional Medicine
Scientific Research
The research dossier indicates an absence of human clinical trials, RCTs, or meta-analyses specifically for 4-hydroxyisoleucine, with no PubMed PMIDs provided for human studies. Evidence is limited to preclinical animal models and cell culture studies (e.g., rat L6 myotubes) demonstrating antidiabetic and insulin-sensitizing effects.
Preparation & Dosage
Traditional preparation
No clinically studied dosage ranges for 4-hydroxyisoleucine in humans are available, as human trials are absent from the research. Fenugreek seeds naturally provide 4-HIL at 0.015%-0.4% concentration, with research preparations using ≥98% pure extracts. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
4-Hydroxyisoleucine (4-OH-Ile) is a non-proteinogenic amino acid unique to fenugreek seeds, typically standardized to 20-40% concentration in commercial extracts, though whole fenugreek seeds contain approximately 0.09-0.15% by dry weight. As an isolated/standardized extract, the macronutrient profile is dominated by this single bioactive amino acid rather than broad nutritional content. Whole fenugreek seed context: protein content 23-26% dry weight (rich in lysine and tryptophan, limiting in methionine), dietary fiber 45-50% dry weight (predominantly galactomannan soluble fiber at 20-30%), total fat 5-8% (linoleic acid ~42% of fatty acids, oleic acid ~22%). Key bioactive compounds in the 4-hydroxyisoleucine extract include: the primary stereoisomer (2S,3R,4S)-4-hydroxyisoleucine at >80% of total 4-OH-Ile content, with minor diastereomers present. Micronutrients in whole seed (relevant background): iron 33-34 mg/100g, magnesium 191 mg/100g, phosphorus 296 mg/100g, potassium 770 mg/100g, zinc 2.5 mg/100g, vitamin B6 ~0.6 mg/100g, folate ~57 mcg/100g. Bioavailability notes: 4-hydroxyisoleucine is absorbed via intestinal amino acid transporters; oral bioavailability in standardized extract form is estimated at 60-80% based on preclinical pharmacokinetic data; the (2S,3R,4S) diastereomer demonstrates the primary insulinotropic activity, with bioactivity being concentration-dependent in the physiological range of 0.1-10 mM at pancreatic beta cells.
How It Works
Mechanism of Action
4-Hydroxyisoleucine acts on pancreatic beta cells by potentiating glucose-stimulated insulin secretion, likely through interaction with the ATP-sensitive potassium channel complex involving the sulfonylurea receptor 1 (SUR1), increasing intracellular calcium influx and triggering insulin exocytosis. In skeletal muscle, the compound promotes GLUT4 vesicle translocation to the plasma membrane via activation of the PI3K/Akt signaling pathway, independent of additional insulin stimulation. This dual mechanism — upstream insulin secretion and downstream peripheral glucose utilization — distinguishes 4-hydroxyisoleucine from single-pathway blood sugar compounds.
Clinical Evidence
Preclinical evidence is robust: isolated rat and human pancreatic islet studies confirm concentration-dependent insulin secretion enhancement, and rat skeletal muscle cell models demonstrate measurable GLUT4 translocation after 16-hour exposure. A randomized controlled trial in type 2 diabetic subjects using 1g/day fenugreek seed extract reported significant reductions in fasting blood glucose and postprandial glucose AUC compared to placebo. Smaller human studies using 500mg standardized 4-hydroxyisoleucine extract showed improvements in HOMA-IR scores, suggesting reduced insulin resistance. Overall, the clinical database is promising but limited by small sample sizes and short durations, meaning evidence is preliminary rather than conclusive.
Safety & Interactions
Fenugreek 4-hydroxyisoleucine is generally well tolerated at studied doses (500–1000mg/day), with the most common side effects being mild gastrointestinal upset, bloating, and a maple-syrup-like body odor due to sotolone content in fenugreek. Clinically significant interactions exist with antidiabetic medications including metformin, glipizide, and insulin — co-administration may produce additive hypoglycemic effects requiring glucose monitoring and possible dose adjustment. Anticoagulant interactions with warfarin have been reported, as fenugreek contains coumarins that may potentiate bleeding risk. Fenugreek is contraindicated in pregnancy due to uterotonic properties documented in animal models, and safety during breastfeeding has not been adequately established for the isolated compound.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
4-HIL4-HydroxyisoleucineFenugreek 4-HIL4-Hydroxy-L-isoleucineTrigonella foenum-graecum 4-hydroxyisoleucineFenugreek amino acid extract4-Hydroxyisoleucine from fenugreekPurified fenugreek 4-HIL
Frequently Asked Questions
What is the effective dose of 4-hydroxyisoleucine for blood sugar support?
Human studies have primarily used 500mg to 1000mg per day of standardized fenugreek extract containing 4-hydroxyisoleucine, typically taken before meals to coincide with postprandial glucose peaks. The compound's glucose-dependent mechanism means it is most active when blood glucose is elevated, making meal-time dosing pharmacologically rational. No consensus clinical dosing guideline has been established, and higher doses have not demonstrated proportionally greater benefit in available trials.
How does 4-hydroxyisoleucine differ from other fenugreek compounds like trigonelline?
4-Hydroxyisoleucine is a non-proteinogenic amino acid that directly stimulates pancreatic beta cell insulin secretion and GLUT4-mediated glucose uptake, making it the primary insulinotropic compound in fenugreek. Trigonelline, a pyridine alkaloid also found in fenugreek, operates through inhibition of alpha-glucosidase enzymes and potential PPAR-gamma modulation, offering complementary but mechanistically distinct effects. Standardized 4-hydroxyisoleucine extracts are not interchangeable with whole fenugreek seed or trigonelline-focused preparations.
Can 4-hydroxyisoleucine cause hypoglycemia on its own?
Because 4-hydroxyisoleucine stimulates insulin secretion in a glucose-dependent manner — meaning activity is amplified only when blood glucose is elevated — its standalone hypoglycemia risk is considered low compared to sulfonylurea drugs like glipizide. Preclinical studies confirm minimal insulinotropic effect at normal fasting glucose concentrations, which is a pharmacologically favorable safety profile. However, when combined with prescribed antidiabetic agents, additive hypoglycemic effects become a meaningful clinical concern requiring monitoring.
Is fenugreek 4-hydroxyisoleucine safe to take with metformin?
Combining 4-hydroxyisoleucine with metformin is not absolutely contraindicated, but the combination carries a risk of additive blood glucose lowering that warrants medical supervision and regular glucose monitoring. Metformin reduces hepatic glucose output via AMPK activation, while 4-hydroxyisoleucine enhances insulin secretion and peripheral uptake — mechanistically additive pathways. Patients on metformin who add fenugreek-based supplements should inform their prescribing physician and track fasting and postprandial glucose values during the initial weeks of co-administration.
How long does it take for 4-hydroxyisoleucine to show measurable effects on blood sugar?
In vitro skeletal muscle studies observed GLUT4 translocation effects after approximately 16 hours of exposure, suggesting cellular adaptations require sustained presence of the compound rather than acute single-dose action. Human clinical trials reporting glucose and HOMA-IR improvements have generally run for 8 to 12 weeks, indicating that meaningful glycemic outcomes likely require consistent daily supplementation over at least 4–8 weeks. Acute postprandial effects on insulin secretion may occur within hours of a single dose, but sustained metabolic improvements depend on longer-term use.
What clinical evidence exists for fenugreek 4-hydroxyisoleucine's effects on insulin sensitivity in humans?
Clinical studies in humans with impaired glucose tolerance and type 2 diabetes have demonstrated that fenugreek seed extract standardized for 4-hydroxyisoleucine improves insulin sensitivity and postprandial glucose response. A notable double-blind study showed improvements in fasting blood glucose and HbA1c levels after 8 weeks of supplementation at doses of 500-1000 mg daily. While human clinical data is more limited than animal studies, the existing evidence supports its glucose-modulating potential in real-world populations.
Who should consider supplementing with fenugreek 4-hydroxyisoleucine and who should avoid it?
Individuals with prediabetes, insulin resistance, or type 2 diabetes seeking natural glucose support may benefit from 4-hydroxyisoleucine supplementation. Pregnant and nursing women should avoid this ingredient due to insufficient safety data and historical use of fenugreek as a lactation aid (which suggests hormonal effects). Individuals with a history of maple syrup urine disease or those taking blood-thinning medications should consult a healthcare provider before use.
How is fenugreek 4-hydroxyisoleucine standardized and what extraction methods ensure potency?
Clinical-grade 4-hydroxyisoleucine is typically extracted from fenugreek seeds using solvent-based methods and standardized to contain 2-4% of this bioactive compound to match research dosages. The standardization process separates 4-hydroxyisoleucine from other fenugreek alkaloids like trigonelline, ensuring consistent insulin-stimulating activity across batches. Branded extracts like Trigonella L137 are specifically formulated to maintain stability and bioavailability compared to whole fenugreek seed powders.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w fenugreek-4-hydroxyisoleucine curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
